INC Research, LLC has launched Research Strategic Advisory Services, a new global business unit dedicated to providing consulting capabilities for drug development and commercialization, regulatory consulting and submissions, and quality assurance.
The new Strategic Advisory Unit includes three practice areas: AVOS Consulting, offering perspectives on the future business environment for healthcare products and services; Regulatory Consulting and Submissions, which offers regulatory expertise across the entire lifecycle of small molecules, proteins and devices; and Compliance Consulting, which works with customers quality assurance departments to provide QA program management.
“We’re excited to offer strategic advisory capabilities to biopharmaceutical companies in a more integrated way,” said Tim Dietlin, senior vice president, Global Consulting and Strategic Alliances and head of the new unit. “Working as an integrated team gives our expert advisors better visibility into our customers’ product development lifecycles and needs, enabling a true strategic partnership to evolve. This model allows greater flexibility and agility to identify opportunities, anticipate challenges and offer a broader range of perspectives and options for how to best address them.”